Anavex Life Sciences (AVXL) Other Non-Current Liabilities (2013)
Anavex Life Sciences (AVXL) posted Other Non-Current Liabilities of $904000.0 for Q3 2013.
Anavex Life Sciences (AVXL) Other Non-Current Liabilities (2013) Analysis & Trends
Anavex Life Sciences has reported Other Non-Current Liabilities for 1 years, with the latest figure at $904000.0 in Q3 2013.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $904000.0 in Q3 2013, while the trailing twelve-month figure through Sep 2013 was $904000.0 (changed N/A YoY) and the FY2013 annual result came in at $904000.0, changed N/A from the prior year.
- Other Non-Current Liabilities held at $904000.0 in Q3 2013 per AVXL's latest filing.
- Over five years, Other Non-Current Liabilities peaked at $904000.0 in Q3 2013 and troughed at $904000.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 904,000.00 |